Meagan Medical

Meagan Medical is a private, clinical-stage medical device company developing advanced electrical stimulation therapies for chronic pain management. Its core technology platform utilizes medium-frequency interferential currents (IFC) and Cutaneous Field Stimulation (CFS) to achieve deeper tissue penetration and longer-lasting pain relief by selectively targeting specific nerve fibers (Aβ and Aδ). The company's pipeline includes the DISCSS spinal cord stimulator system in development and the CFS device, which is supported by preclinical and clinical research. Meagan Medical operates in the large and growing neuromodulation market, aiming to offer cost-effective, non-opioid alternatives for pain management.

Proprietary electrical stimulation therapies utilizing Interferential Current (IFC) and Cutaneous Field Stimulation (CFS). IFC uses intersecting medium-frequency currents for deep tissue penetration, while CFS selectively stimulates Aβ and Aδ nerve fibers for prolonged peripheral pain relief.

Meagan Medical competes in the highly competitive neuromodulation market dominated by large players like Medtronic, Boston Scientific, and Abbott. Its DISCSS system must differentiate from existing SCS technologies, while its CFS device competes with a wide range of TENS units and other non-invasive neurostimulation devices.